Compassionate Use Program for Trifluridine/Tipiracil (TAS-102) in Metastatic Colorectal Cancer: A Real-Life Overview


U.O. Oncologia Medica, Seconda Università degli Studi di Napoli, Napoli, Italy; Medica Oncologica, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; G. Zocchi Medica 1, Istituto di Biologia e Medicina della Tumore, Ferrara, Italy; Oncologia Medica, Università Cattolica del Sacro Cuore, Roma, Italy, Department of Medicine, University of Padua, Padua, Italy, Department of Medicine, University of Verona, Verona, Italy

INTRODUCTION

Trifluridine/tipiracil (TAS-102) is an oral chemotherapeutic combination treatment comprised of trifluridine (FTD) and tipiracil (TPI). The trifluridine/tipiracil (TAS-102) CUP, set up prior to marketing authorization for management of pretreated metastatic colorectal cancer, was designed in all countries with data for each parameter from the RECOURSE trial.

METHODS

Patients with mCRC who have been previously treated with an or anti-vascular endothelial growth factor (VEGF) therapy, and an or anti-VEGF therapy, with or without prior fluoropyrimidines, if previously treated with fluoropyrimidines.

Patients who are not on any investigational or any other anticancer medications, and who have not received any investigational or any other anticancer medication prior to the start of the study.

Patients should not receive any other investigational or any other anticancer therapy during the study.

Figure 2. Disposition, dose modification and permanent discontinuation for patients in the CUP

Figure 1. Baseline characteristics of patients treated in the CUP and in the phase 3 RECOURSE trial

Table 4. Baseline characteristics of patients treated in the CUP and in the phase 3 RECOURSE trial

Table 5. Recommended dose modifications for trifluridine/tipiracil in case of hematological and non-hematological adverse reactions

Table 6. Dose interruption and rechallenge criteria for hematological toxicities related to epoetin-pretreated CUP

Table 3. Trifluridine/tipiracil CUP by country: patients who received treatment

Table 2. Recommended dose modifications for trifluridine/tipiracil in case of hematological and non-hematological adverse reactions

Table 1. Summary of dose modifications for trifluridine/tipiracil

RESULTS

The findings from this descriptive analysis are consistent with those reported in the phase 3 RECOURSE trial and with relevant previous published reports.

CONCLUSIONS

The trifluridine/tipiracil (TAS-102) CUP set up prior to marketing authorization for management of pretreated metastatic colorectal cancer (mCRC) in metastatic colorectal cancer (mCRC), is a real-life international compassionate use program that can provide an earlier access to treatment for patients with unmet medical needs.

REFERENCES